2.23
price down icon1.33%   -0.03
after-market Handel nachbörslich: 2.23
loading
Schlusskurs vom Vortag:
$2.26
Offen:
$2.27
24-Stunden-Volumen:
146.02K
Relative Volume:
0.37
Marktkapitalisierung:
$234.62M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-5.887
EPS:
-0.3788
Netto-Cashflow:
$21.84M
1W Leistung:
-1.33%
1M Leistung:
+3.24%
6M Leistung:
+3.24%
1J Leistung:
+18.30%
1-Tages-Spanne:
Value
$2.17
$2.27
1-Wochen-Bereich:
Value
$2.1076
$2.39
52-Wochen-Spanne:
Value
$1.07
$4.62

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name
Firmenname
Proqr Therapeutics N V
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
166
Name
Twitter
@proqr
Name
Nächster Verdiensttermin
2025-03-14
Name
Neueste SEC-Einreichungen
Name
PRQR's Discussions on Twitter

Vergleichen Sie PRQR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PRQR
Proqr Therapeutics N V
2.23 238.08M 7.05M -30.43M 21.84M -0.3788
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-29 Fortgesetzt Cantor Fitzgerald Overweight
2025-04-29 Eingeleitet Evercore ISI Outperform
2025-03-10 Hochstufung Citigroup Neutral → Buy
2025-01-10 Eingeleitet Oppenheimer Outperform
2024-10-29 Hochstufung Raymond James Outperform → Strong Buy
2023-11-08 Hochstufung Chardan Capital Markets Neutral → Buy
2023-03-30 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2022-12-22 Hochstufung Cantor Fitzgerald Neutral → Overweight
2022-02-14 Herabstufung Citigroup Buy → Neutral
2022-02-11 Herabstufung Raymond James Strong Buy → Mkt Perform
2022-02-11 Herabstufung Stifel Buy → Hold
2022-02-01 Eingeleitet Raymond James Strong Buy
2021-05-03 Eingeleitet Stifel Buy
2021-03-25 Bestätigt Citigroup Buy
2020-11-03 Fortgesetzt Cantor Fitzgerald Overweight
2019-03-12 Bestätigt Chardan Capital Markets Buy
2018-12-19 Eingeleitet RBC Capital Mkts Outperform
2018-11-15 Eingeleitet Citigroup Buy
2018-09-19 Eingeleitet Evercore ISI Outperform
2017-09-26 Bestätigt JMP Securities Mkt Outperform
2016-06-20 Eingeleitet Chardan Capital Markets Neutral
2014-10-15 Eingeleitet Deutsche Bank Buy
2014-10-13 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten

pulisher
01:14 AM

Brokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $8.00 - Defense World

01:14 AM
pulisher
Jul 27, 2025

What institutional investors are buying ProQR Therapeutics N.V. stockFree Consultation - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Does ProQR Therapeutics N.V. stock perform well during market downturnsCapitalize on emerging investment opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

When is ProQR Therapeutics N.V. stock expected to show significant growthUnbelievable profit margins - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is ProQR Therapeutics N.V. stock a growth or value playFree Real-Time Stock Data - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Is ProQR Therapeutics N.V. stock overvalued or undervaluedInvest smarter with daily market updates - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Buy Signal for ProQR Therapeutics N.V. Stock Key Technical Indicators to WatchFree Investment Community - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

How ProQR Therapeutics N.V. stock performs during market volatilityFree Stock Market Strategy Classes - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Why ProQR Therapeutics N.V. stock attracts strong analyst attentionBest Stocks for Capital Safety - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

ProQR Therapeutics N.V. Company Revenue and Profit Trends: A Deep DiveFree Stock Market Beginners Guide - Newser

Jul 27, 2025
pulisher
Jul 25, 2025

Is ProQR Therapeutics N.V. a good long term investmentFree Popular Stock Recommendations - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

ProQR Therapeutics N.V. Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Will ProQR Therapeutics N.V. stock benefit from interest rate changesAccelerated financial growth - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What drives ProQR Therapeutics N.V. stock priceStrong return on assets - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about ProQR Therapeutics N.V. stockUnprecedented profit potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 21, 2025

Owning 32% shares,institutional owners seem interested in ProQR Therapeutics N.V. (NASDAQ:PRQR), - Yahoo Finance

Jul 21, 2025
pulisher
Jul 17, 2025

ProQR stock rating reiterated by Cantor Fitzgerald ahead of key 2H25 data - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 15, 2025

What makes ProQR Therapeutics N.V. stock price move sharplyFree Wealth-Building Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) high institutional ownership speaks for itself as stock continues to impress, up 16% over last week - simplywall.st

Jul 15, 2025
pulisher
Jul 14, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Acquired by OneDigital Investment Advisors LLC - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat

Jul 11, 2025
pulisher
Jul 10, 2025

Vontobel Holding Ltd. Invests $48,000 in ProQR Therapeutics N.V. (NASDAQ:PRQR) - Defense World

Jul 10, 2025
pulisher
Jul 07, 2025

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Australia

Jul 07, 2025
pulisher
Jul 06, 2025

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles By Investing.com - Investing.com South Africa

Jul 06, 2025
pulisher
Jul 03, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat

Jul 03, 2025
pulisher
Jun 30, 2025

ProQR Therapeutics' (PRQR) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat

Jun 30, 2025
pulisher
Jun 28, 2025

ProQR Therapeutics (NASDAQ:PRQR) Given Market Outperform Rating at JMP Securities - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stoc - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target By Investing.com - Investing.com Canada

Jun 27, 2025
pulisher
Jun 27, 2025

ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target - Investing.com

Jun 27, 2025

Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):